← Back to Search

Virus Therapy

GLS-1200 for COVID-19

Phase 2
Waitlist Available
Research Sponsored by GeneOne Life Science, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 4 weeks of treatment
Awards & highlights

Study Summary

This trial will test if a nasal spray can reduce the risk of infection from the coronavirus.

Eligible Conditions
  • COVID-19
  • Infections

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~4 weeks of treatment
This trial's timeline: 3 weeks for screening, Varies for treatment, and 4 weeks of treatment for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Evaluate the number of GLS-1200 topical nasal spray adverse events as assessed by CTCAE v5.0
Incidence of SARS-CoV-2 infection, confirmed by PCR relative to treatment group
Secondary outcome measures
Symptom score of documented SARS-CoV-2 infection relative to treatment group with a higher score being a worse outcome.

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: GLS-1200Experimental Treatment1 Intervention
1 mL of GLS-1200 per nostril, TID
Group II: 0.9 %SalinePlacebo Group1 Intervention
1 mL of 0.9% Saline per nostril, TID

Find a Location

Who is running the clinical trial?

GeneOne Life Science, Inc.Lead Sponsor
15 Previous Clinical Trials
1,256 Total Patients Enrolled
4 Trials studying COVID-19
414 Patients Enrolled for COVID-19

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who else is applying?

What state do they live in?
Texas
How old are they?
18 - 65
What site did they apply to?
Conroe Willis Medical Reasearch
What portion of applicants met pre-screening criteria?
Met criteria
Recent research and studies
clinicaltrials.govStudy
GLS-1200 Topical Nasal Spray to Prevent SARS-CoV-2 Infection (COVID-19)
2020. "GLS-1200 Topical Nasal Spray to Prevent SARS-CoV-2 Infection (COVID-19)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04408183.
~38 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top